eMedevents
  • 143,476+ Medical Conferences
  • 281 Specialties
  • 10,815 Organizers
  • 154,041 Speakers
  • 156 Countries
  • 4,643 Cities
47,825+
CME Conference Registrations Sold
Home  >  Speakers  >  Lucie Bruijn
Lucie Bruijn

Lucie Bruijn

     PhD, MBA
Chief Scientist | District of Columbia, Washington    United States of America
Clinical Pharmacology, Research And Clinical Research
Sporadic ALS Patients, ALS,...More
Spoken at 5 events

Biography :

Lucie Bruijn, Ph.D. joined The ALS Association (ALSA) in January 2001 and is currently the Chief Scientist. Prior to that Dr. Bruijn led a team at Bristol Myers Squibb developing in vitro and in vivo model systems for neurodegenerative disease. Realizing the potential of stem cell therapy for neurodegenerative diseases, her team worked with experts in academia to establish stem cell studies at Bristol Myers Squibb.

Dr. Bruijn received her Bachelor’s degree in Pharmacy at Rhodes University, South Africa. She received a Master’s degree in Neuroscience and a Ph.D. in Biochemistry, specializing in disease mechanisms of Alzheimer’s disease, at the University of London, United Kingdom. She received her MBA at Imperial College, London, United Kingdom. She joined Dr. Don Cleveland’s laboratory in 1994 where she developed and characterized a mouse model of ALS (mice expressing the familial-linked SOD1 mutation). Using this model her studies focused on disease mechanisms. In addition, in collaboration with Dr. Robert Brown she looked for neurofilament mutations in familial and sporadic ALS patients.

At The ALS Association, Dr. Bruijn leads a global ALS research effort, Translational Research to Advance Therapies for ALS (TREAT ALS™) with the goal to move treatment options from “bench to beside.” She has made it a priority to collaborate with other funding agencies, in particular The National Institute of Health, The Department of Defense and many other not-for-profit ALS organizations, as well as other foundations focusing on neurodegenerative research. These collaborations ensure that increased dollars are spent on ALS research. She is involved in project development, encouraging partnerships with academia and biotech, and has played a key role in forging collaborations amongst investigators. It is her strong belief that only through collaboration among a wide range of disciplines will we be successful in changing the course of ALS and finding a cure.

Through participation at scientific meetings both nationally and internationally ALSA receives wide-spread recognition amongst the scientific community. Dr. Bruijn represents The ALS Association on several scientific and research committees world-wide and acts as advisor to scientists, government officials and industry leaders seeking council in the field of ALS research. She continues to publish in the field in peer-reviewed journals and remains actively engaged in understanding the most recent research developments.

***********************
**********
   
For speaker's contact information - Contact us

Specialties

Clinical Pharmacology, Research and Clinical Research

Interested Topics

Sporadic ALS patients, ALS, Stem cell therapy, Neurodegenerative diseases, SOD1 mutation, Neurofilament mutations

State Licenses

This section has yet to be updated by the speaker.

Board Certifications

This section has yet to be updated by the speaker.

Professional Association

This section has yet to be updated by the speaker.

Languages

English

Conference Session Materials

The conference session material has yet to be added by the speaker.
Close

Send Message